2022-12-23T15:11:05-06:00 2022-06-30 930900579 MCDONALD JACOBS PC 520 SW YAMHILL ST STE 500 PORTLAND OR 97204 990 2021-07-01 930571472 NATIONAL PSORIASIS FOUNDATION NATI 5032447404 6600 SW 92ND AVENUE 300 PORTLAND OR 97223 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 5032447404 2022-12-20 1 RONALD GOLDSMAN 999009999 SANG AHN P00540880 5032270581 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z LEAH MCCORMICK HOWARD 6600 SW 92ND AVENUE 300 PORTLAND OR 97223 15517720 0 X WWW.PSORIASIS.ORG X 1968 OR TO DRIVE EFFORTS TO CURE PSORIATIC DISEASE AND IMPROVE THE LIVES OF THOSE AFFECTED. 17 17 71 740 960482 166495 11146561 11642853 1228158 1766970 367378 303148 -84431 -322618 12657666 13390353 2809557 3215178 0 0 5444914 5787201 203911 203911 1285546 2671352 3331820 11129734 12538110 1527932 852243 15989040 13977875 5053003 3425275 10936037 10552600 X THE NATIONAL PSORIASIS FOUNDATION PROVIDES PEOPLE WITH PSORIASIS AND PSORIATIC ARTHRITIS THE SERVICES THEY NEED TO BEST MANAGE THEIR CONDITION, WHILE PROMOTING RESEARCH TO FIND A CURE. 0 0 4635370 3215178 9616 RESEARCH NPF CONTINUED TO LEAD COLLABORATIVE, TRANSFORMATIONAL RESEARCH BY ENSURING THAT FUNDING EXTRAMURAL RESEARCH REMINED A PRIORITY. IN FY 2022, NPF INVESTED OVER $3.2M IN RESEARCH GRANTS AND FELLOWSHIPS. NPF COMPETITIVE RENEWAL OF THE PSORIASIS PREVENTION INITIATIVE GRANT RESULTED IN THE GREATEST SINGLE AWARD IN NPF HISTORY. THIS GRANT SUPPORTS A MULTI-INSTITUTIONAL, MULTI-DISCIPLINARY TEAM WITH THE GOAL OF IDENTIFYING AN INTERVENTION THAT WILL PREVENT PSORIATIC DISEASE COMORBIDITIES. THE PSA DIAGNOSTIC TEST GRANT WAS ALSO RENEWED FOR TWO INSTITUTIONS WORKING TO DEVELOP A DIAGNOSTIC TEST FOR PSORIATIC ARTHRITIS (PSA). NPF CONTINUED ITS INVESTMENT IN THE MORE THAN SKIN DEEP MENTAL HEALTH GRANT, WHICH FUNDS RESEARCH AIMED AT ADDRESSING MENTAL HEALTH ISSUES, A MAJOR PSORIATIC DISEASE COMORBIDITY. THE NPF HELD BOTH A RESEARCH SYMPOSIUM AND COLLOQUIUM, COLLABORATED WITH PUBLIC-PRIVATE PARTNERS IN THE ACCELERATED MEDICINES PARTNERSHIP FOR AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES INITIATIVE, PUBLISHED SEVERAL ABSTRACTS AND PAPERS, AND BROUGHT THE INTERNALLY GENERATED DATA TO THE COMMUNITY. NPF ALSO PUBLISHED AN INFOGRAPHIC TO EDUCATE OTHERS ABOUT PSORIASIS BEING A SYSTEMIC, IMMUNE-MEDIATED DISEASE WITH SEVERAL COMORBIDITIES IMPACTING OVERALL HEALTH OUTCOMES. 1045101 200000 PROFESSIONAL EDUCATIONNPF CONTINUED TO EXPAND AND STRENGTHEN MEDICAL EDUCATION PROGRAMMING TARGETING HEALTH CARE PROVIDERS AT ALL LEVELS AND STAGES OF CAREER. THE 23RD ANNUAL NPF RESIDENTS' MEETING OFFERED DERMATOLOGY RESIDENTS THE LATEST IN PSORIATIC DISEASE TREATMENT PRESENTED BY EXPERTS IN THE FIELD. NPF LAUNCHED A FIRST OF IT'S KIND, MEDICAL SCHOOL CURRICULUM TO HELP STUDENTS GAIN A DEEPER UNDERSTANDING OF PSORIATIC DISEASE. NPF CONTINUED TO FOCUS EFFORTS ON COLLABORATION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS, WHICH IS ESSENTIAL TO IMPROVE THE DIAGNOSIS AND TREATMENT OF PSA. NPF ALSO INCORPORATED A FOCUS ON COLLABORATIVE CARE BETWEEN ALL PROVIDERS WITHIN A PRACTICE, PARTICULARLY ADVANCED PROVIDERS AND OTHER SPECIALTIES SUCH AS CARDIOLOGISTS. THIS ENGAGEMENT ALSO INCLUDE OUTREACH TO HEALTH INSURERS TO SUPPORT THEIR UNDERSTANDING OF PSORIATIC DISEASE. 983215 ADVOCACYNPF CONTINUED TO ADVOCATE ON BOTH STEP THERAPY AND COPAY ACCUMULATOR ADJUSTMENT PROGRAMS TO ENSURE PATIENTS HAVE AFFORDABLE ACCESS TO THERAPIES. TO DATE, MORE THAN 42 BILLS (30 STEP THERAPY, 12 COPAY ACCUMULATOR) HAVE BECOME LAW. NPF ALSO LEVERAGED THOUSANDS OF ADVOCATES TO WORK FOR HEALTH INSURANCE COVERAGE IMPROVEMENTS FOR THE MILLIONS OF PEOPLE LIVING WITH PSORIATIC DISEASE, WHILE ALSO WORKING TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSA TREATMENTS AND INCREASING FEDERAL SUPPORT FOR PSORIATIC DISEASE RESEARCH. 3025224 597468 EDUCATION, OUTREACH, AND PATIENT SERVICESNPF SECURED A 3-YEAR GRANT FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION CHRONIC DISEASE EDUCATION AND AWARENESS (CDEA) PROGRAM TOTALING NEARLY $1 MILLION TO RAISE AWARENESS ABOUT PSORIASIS AS AN IMMUNE-MEDIATED, SYSTEMIC INFLAMMATORY DISEASE AMONG THE GENERAL PUBLIC, PUBLIC HEALTH PROFESSIONALS, AND HEALTH CARE PROVIDERS. FUNDING FROM THIS GRANT HAS SUPPORTED NPF CONTINUING MEDICAL EDUCATION (CME) PROGRAMS, PATIENT NAVIGATION CENTER (PNC), AND NPF OUTREACH AND AWARENESS ACTIVITIES.THROUGH THE NPF PATIENT NAVIGATION CENTER, ALMOST 18,000 PATIENTS RECEIVED FREE, PERSONALIZED SUPPORT DESIGNED TO HELP THEM UNDERSTAND PSORIATIC DISEASE AND TREATMENT OPTIONS, NAVIGATE INSURANCE CHALLENGES, AND FIND THE APPROPRIATE HEALTH CARE PROVIDER. NPF ADVANCE MAGAZINE CONTINUED TO PROVIDE THE LATEST INFORMATION, STORIES, AND RESOURCES FIVE TIMES ANNUALLY FOR OVER 21,000 PRINT SUBSCRIBERS AND HUNDREDS OF THOUSANDS OF ONLINE READERS. EACH WEEK, MORE THAN 138,000 PEOPLE RECEIVED ADVANCE WEEKLY, THE OFFICIAL PATIENT-FOCUSED E-NEWSLETTER OF NPF.NPF PROVIDED A COMPREHENSIVE SET OF EDUCATIONAL AND INFORMATIONAL RESOURCES TO THE 4,085,982 VISITORS TO PSORIASIS.ORG AND ASSOCIATED SITES, AND INTERACTED WITH OVER 135,000 PEOPLE FROM THE COMMUNITY ON SOCIAL MEDIA CHANNELS (FACEBOOK, TWITTER, INSTAGRAM, LINKEDIN). 3025224 597468 9688910 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 85 0 71 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X RONALD GOLDSMAN 5032447404 6600 SW 92ND AVENUE 300 PORTLAND OR 97223 RON GRAU CHAIR 1.00 X X 0 0 0 CAROL OSTROW CHAIR-ELECT 1.00 X X 0 0 0 EYAL OFIR VICE CHAIR 1.00 X X 0 0 0 MIKE REFERMAT TREASURER 1.00 X X 0 0 0 RICHARD SEIDEN SECRETARY 1.00 X X 0 0 0 RAYMOND CHIP NEWTON PAST CHAIR 1.00 X 0 0 0 JONATHAN SCOTT DIRECTOR 1.00 X 0 0 0 LARRY GREEN MD DIRECTOR 1.00 X 0 0 0 JODI WOOD DIRECTOR 1.00 X 0 0 0 JERRY BAGEL MD DIRECTOR 1.00 X 0 0 0 MICHAEL GRAFF DIRECTOR 1.00 X 0 0 0 MARK OBERMAN DIRECTOR 1.00 X 0 0 0 JASON LICHTEN MD DIRECTOR 1.00 X 0 0 0 PETE MILLER DIRECTOR 1.00 X 0 0 0 MATTHEW T KISELICA DIRECTOR 1.00 X 0 0 0 APRIL ARMSTRONG MD DIRECTOR 1.00 X 0 0 0 ELAINE HUSNI MD DIRECTOR 1.00 X 0 0 0 JOHN ROGACKI THRU FEB 2022 CHIEF FINANCIAL OFFICER 40.00 X 191632 0 15331 RANDY BERANEK THRU DEC 2021 PRESIDENT/CEO 40.00 X 406258 0 27921 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 40.00 X 0 0 0 STACIE BELL THRU JAN 2022 CHIEF SCIENTIFIC AND MEDICAL OFFICER 40.00 X 228810 0 28535 LEAH MCCORMICK HOWARD COO (THRU DEC); INTERIM PRESIDENT/CEO (JAN - JUNE) 40.00 X 212967 0 22823 KRISTINE BOCKMIER VICE PRESIDENT OF FIELD OPERATIONS 40.00 X 130745 0 18693 ANDREA CLAY VP OF CORPORATE PARTNERSHIPS 40.00 X 114212 0 6407 MICHAEL MACLOED DIRECTOR OF PRINCIPAL GIVING 40.00 X 135107 0 19062 KATHERINE SOUTHWICK DIRECTOR OF MARKETING & COMMUNICATIONS 40.00 X 102419 0 12862 1522150 0 151634 8 0 1 0 CONVERO 835 SHARON DRIVE SUITE 200 CLEVELAND DC 44145 PUBLICATION DEVELOPMENT AND DISTRIBUTION 158418 BENTZ WHALEY FLESSNER AND ASSOCIATES IN 7900 XERXES AVE SOUTH SUITE 980 MINNEAPOLIS MD 55431 CONSULTING 115219 2 69268 36755 2532970 1265132 7738728 385705 11642853 ADVERTISING INCOME 541800 960482 960482 PRODUCT CERTIFICATION 541900 415156 415156 SCIENTIFIC ADVISORY 541900 200000 200000 PATIENT RECRUITMENT 541900 169249 169249 CONSULTING 541900 12467 12467 9616 9616 1766970 177839 177839 36983 36983 1892479 1767170 125309 125309 125309 0 2532970 360197 -360197 -360197 596 0 596 596 13390353 807084 960482 -20066 2810178 2810178 405000 405000 1134276 823494 186110 124672 3834159 2783633 629103 421423 130284 94587 21377 14320 342824 248893 56250 37681 345658 250951 56715 37992 50387 31476 9403 9508 19550 19550 199263 199263 203911 203911 32211 32211 977226 625896 226958 124372 175990 158792 17198 714695 419624 117132 177939 341891 248213 56104 37574 642349 528650 49125 64574 53445 38801 8770 5874 TAXES 94360 94360 30453 21459 486 8508 12538110 9688910 1563654 1285546 X 4976495 2356360 1043672 2277242 470405 512018 9541 6666 239985 127501 934391 426347 133780 508044 9084998 8159880 30164 30164 15989040 13977875 844518 873517 2861131 2312500 210437 160792 1136917 78466 5053003 3425275 X 9837008 7475871 1099029 3076729 10936037 10552600 15989040 13977875 852243 -1235680 0 X X 0 1 X 1 0 X 13408527 13168307 12708368 11146561 11642853 62074616 13408527 13168307 12708368 11146561 11642853 62074616 22845491 39229125 89858 124320 216849 164668 214822 810517 637300 1116715 1291031 1065032 185995 4296073 67181206 4350061 0.58390 0.57190 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 69888 83777 153665 11066688 11220353 711018 177755 0 0 711673 744630 616452 711018 2783773 4175660 430252 448606 199263 153665 1231786 177918 186158 154113 177755 695944 1043916 18486 25348 69888 113722 370000 370000 32132 26155 5977 354686 343126 11560 177573 57066 120507 508044 DEFERRED RENT 37421 GIFT ANNUITY LIABILITY 31891 DEFERRED COMPENSATION PLAN 9154 78466 X 12122462 -1235680 -1235680 13358142 32211 32211 13390353 12505899 0 12505899 32211 32211 12538110 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISION OF FASB ASC TOPIC 740 OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND CONCLUDED THAT THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS TOPIC. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT EXPENSES MORE THAN SKIN DEEP - MENTAL HEALTH & SUMMER STUDENT RESEARCH GRANT 105000 NORTH AMERICA 0 0 GRANT EXPENSES PSA DIAGNOSTIC AWARD 300000 0 0 0 0 0 0 405000 0 405000 SWEDEN MORE THAN SKIN DEEP - MENTAL HEALTH 100000 BANK DRAFT 0 CANADA PSA DIAGNOSTIC TEST GRANT 300000 BANK DRAFT 0 0 0 0 0 0 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. PART III ACCOUNTING METHOD: X X X X X X 0 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY TEAM NPF 1565936 1565936 21321 58176 41564 2261 19417 CHICAGO GALA 761735 761735 2535 66069 47203 1200 22661 1 205299 205299 2100 33178 23704 18808 2532970 2532970 25956 157423 112471 3461 60886 360197 -360197 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 022155491 042103881 501 (C)(3) 50000 0 PSORIASIS DISEASE RESEARCH FELLOWSHIP EMORY UNIVERSITY 201 DOWMAN DR NE 408 ATLANTA GA 30322 580566256 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD CLEVELAND CLINIC FOUNDATION 6801 BRECKSVILLE RD RK1-85 INDEPENDENCE OH 441315032 912153073 501 (C)(3) 50000 0 EARLY CAREER RESEARCH GRANT NEW YORK UNIVERSITY SCHOOL OF MEDICINE PO BOX 415026 BOSTON MA 022415026 135562308 501 (C)(3) 350000 0 PSA DIAGNOSTIC TEST GRANT NORTHWESTERN UNIVERSITY - CHICAGO CAMPUS 201 E HURON ST CHICAGO IL 60611 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 316025986 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 SAN FRANCISCO CA 94143 946036493 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 SAN FRANCISCO CA 94143 946036493 501 (C)(3) 100000 0 BRIDGE GRANT REGENTS OF THE UNIVERSITY OF CALIFORNIA (UNIVERSITY OF CALIFORNIA DAVIS) PO BOX 989062 WEST SACRAMENTO CA 957989062 946036494 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD REGENTS OF THE UNIVERSITY OF MICHIGAN 1910 TAUBMAN CENTER ANN ARBOR MI 48109 386006309 501 (C)(3) 100000 0 TRANSLATIONAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIGAN 1910 TAUBMAN CENTER ANN ARBOR MI 48109 386006309 501 (C)(3) 50000 0 EARLY CAREER RESEARCH GRANT TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 19178 231352685 501 (C)(3) 1500000 0 PPI AWARD TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 19178 231352685 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA ST STE 102 LOS ANGELES CA 900898001 951642394 501 (C)(3) 50000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP AWARD 14 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND FISCAL PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. X X X X 0 1 0 1 0 1 0 1 0 RANDY BERANEK THRU DEC 2021 PRESIDENT/CEO 367258 0 39000 0 0 0 14500 0 13421 0 434179 0 0 0 STACIE BELL THRU JAN 2022 CHIEF SCIENTIFIC AND MEDICAL OFFICER 218810 0 10000 0 0 0 11542 0 16993 0 257345 0 0 0 LEAH MCCORMICK HOWARD COO (THRU DEC); INTERIM PRESIDENT/CE 196967 0 16000 0 0 0 20249 0 2574 0 235790 0 0 0 JOHN ROGACKI THRU FEB 2022 CHIEF FINANCIAL OFFICER 182632 0 9000 0 0 0 6611 0 8720 0 206963 0 0 0 MICHAEL MACLOED DIRECTOR OF PRINCIPAL GIVING 132307 0 2800 0 0 0 7063 0 11999 0 154169 0 0 0 PART I, LINE 4B CHANGE OF CONTROL PAYMENT: - NONE EMPLOYER CONTRIBUTIONS TO 457(F) DEFERRED COMPENSATION PLAN: LEAH MCCORMICK HOWARD - $10,000 EMPLOYER CONTRIBUTIONS TO 401K: RANDY BERANEK - $14,500 JOHN ROGACKI - $6,611 LEAH MCCORMICK HOWARD - $10,249 STACIE BELL - $11,542 MICHAEL MACLOED - $7,063 PART I, LINE 5 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. PART I, LINE 6 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. PART I, LINE 7 THE EXECUTIVE TEAM PERFORMANCE-BASED BONUS PORTION OF COMPENSATION WAS BASED ON A COMBINATION OF THE EMPLOYEE'S PERFORMANCE AGAINST THEIR INDIVIDUAL OBJECTIVES, THE NPF MEETING ITS ANNUAL REVENUE AND NET INCOME TARGETS. THE FOUNDATION ACKNOWLEDGES ALL OF ITS OTHER EMPLOYEES THROUGH ANNUAL LUMP-SUM INCENTIVE AWARDS BASED ON MEETING INDIVIDUAL OBJECTIVES AND THE NPF MEETING ITS ANNUAL NET REVENUE AND NET INCOME TARGETS. X 5 15705 FMV ON THE DATE RECEIVED X LAND HELD FOR SALE 1 370000 FMV ON THE DATE RECE 1 0 1 1 PART I, LINE 32B: THE ORGANIZATION USES AN OUTSIDE COMPANY THAT RECEIVES DONATED AUTOMOBILES AND SELLS THEM ON BEHALF OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS EMAILED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO ITS BEING FILED ELECTRONICALLY WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C WE HAVE A CONFLICT OF INTEREST POLICY THAT IS SIGNED BY ALL DIRECTORS ANUALLY. ALL DIRECTORS AND KEY EMPLOYEES REFRAIN FROM VOTING OR COMMENTING ON ANYTHING WHERE THERE COULD BE A CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS ANNUALLY REVEIWS AND APPROVES THE CEO'S COMPENSATION. THE FOUNDATION UTILIZES AN INDEPENDENT COMPENSATION CONSULTANT AND SUBSCRIBES TO A SALARY SURVEY FOR COMPARABLE INFORMATION FOR SALARIES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. AUDTIED FINANCIAL STATEMENTS ARE ALSO DISPLAYED ON THE WEBSITE. FORM 990, PART XII, LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.